A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)

Trial Profile

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs SL 701 (Primary) ; Bevacizumab; Poly ICLC
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
    • 03 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
    • 21 Feb 2017 according to a Stemline Therapeutics media release, this trial has been completed and patients are being followed to assess survival. Further updates from the trial are expected later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top